scholarly article | Q13442814 |
P356 | DOI | 10.1016/S0140-6736(62)91782-8 |
P698 | PubMed publication ID | 13866047 |
P2093 | author name string | R I BAYLISS | |
E A HARVEY-SMITH | |||
P2860 | cites work | Inhibition of dihydroxy-phenylalanine decarboxylase by derivatives of phenylalanine | Q73580446 |
Clinical pharmacology of newer anthypertensive agents, monoamine oxidase and decarboxylase inhibitors, bretvlium tosvlate, and guanethidine | Q78848949 | ||
Decarboxylase Inhibition and Blood Pressure Reduction by α-Methyl-3,4-Dihydroxy-DL-phenylalanine | Q78849316 | ||
Clinical and pharmacological studies with guanethidine in the treatment of hypertension | Q79216756 | ||
Serotonin synthesis in carcinoid patients. Its inhibition by alpha-methyl-dopa, with measurement of associated increases in urinary 5-hydroxytryptophan | Q79264295 | ||
P433 | issue | 7233 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | methyldopa | Q412621 |
P304 | page(s) | 763-768 | |
P577 | publication date | 1962-04-01 | |
P1433 | published in | The Lancet | Q939416 |
P1476 | title | Methyldopa in the treatment of hypertension | |
P478 | volume | 1 |
Q72338050 | 3. Animal experimentation leading to the development of drugs benefiting human beings and animals |
Q35440834 | ALPHA-METHYLDOPA IN THE TREATMENT OF HYPERTENSION. |
Q35539765 | Beta-adrenoreceptor blockade in hypertension |
Q55037511 | CLINICAL TRIAL OF 2-GUANIDINOMETHYL (1,4) BENZODIOXAN (COMPOUND 1003). |
Q39261746 | Diuretics as initial treatment for essential hypertension |
Q55690431 | Double-blind trial of four hypotensive drugs (methyldopa and three sympatholytic agents). |
Q49188263 | Effect of Antihypertensive Drugs on the "Intrinsic" Heart Rate |
Q54702184 | Effects of Alpha‐Methyldopa on the Myocardial Blood Flow, Utilizing the Coincidence Counting Method |
Q39368587 | Efficacy of antihypertensive drugs |
Q68896519 | Guanabenz: a centrally acting, natriuretic antihypertensive drug |
Q42055744 | HAeMODYNAMIC STUDIES WITH METHYLDOPA: EFFECT ON CARDIAC OUTPUT AND RESPONSE TO PRESSOR AMINES |
Q84948186 | Hyperpyrexia During Treatment with Methyldopa |
Q95810701 | METHYLDOPA IN TREATMENT OF HYPERTENSION DUE TO CHRONIC RENAL DISEASE |
Q55352982 | METHYLDOPA IN TREATMENT OF SEVERE TOXAEMIA OF PREGNANCY. |
Q24240065 | Methyldopa for primary hypertension |
Q42234359 | Methyldopa hepatitis. Report of three cases |
Q84947699 | Methyldopa in Hypertension |
Q72755050 | Methyldopa in hypertension |
Q44094662 | Multicentre General Practitioner Assessment of ‘Tenormin’ and Methyldopa |
Q42184545 | Natriuretic and water diuretic effects of guanabenz, a central alpha-2 agonist |
Q67441269 | Oxprenolol in Hypertension. A Report on 2,770 Patients in General Practice Originally Treated with Methyldopa |
Q71776920 | Relationship of extracellular fluid volume to the development of drug resistance in the hypertensive patient |
Q41391081 | SOME OBSERVATIONS ON THE PHARMACOLOGY OF ALPHA-METHYLDOPA. |
Q28363952 | Side Effects of Hypotensive Agents Evaluated by a Self-administered Questionnaire |
Q36770574 | Some aspects of the long-term treatment of severe hypertension with methyldopa |
Q40817384 | Stereochemical course in vivo of alpha-methyldopa decarboxylation in rat brains |
Q44083117 | Studies on the pharmacology of α-methyl-3,4-dihydroxyphenylalanine (α-methyl-DOPA) and α-methylnorepinephrine Part II |
Q76851018 | THE PROLONGED USE OF ALPHA METHYLDOPA IN THE TREATMENT OF HYPERTENSION |
Q42918796 | The metabolism of14C-labelled α-methyldopa in normal and hypertensive human subjects |
Q93744937 | To-day's Drugs |
Q93932663 | To-day's Drugs |
Q93664186 | Treatment of Pre-eclampsia or Toxaemia of Pregnancy |
Q71166827 | Treatment of hypertension with methyldopa |
Q79512594 | Treatment of severe hypertension with methyldopa |
Q79614651 | [The effect of intravenously administered DOPA on the blood pressure in pretreated alpha-methyl-DOPA hypertensives. Studies on the blood pressure-lowering mechanism of alpha-methyl-DOPA] |